1.92
-0.06(-3.03%)
Currency In USD
| Previous Close | 1.98 |
| Open | 1.98 |
| Day High | 2.01 |
| Day Low | 1.91 |
| 52-Week High | 3.95 |
| 52-Week Low | 0.69 |
| Volume | 253,742 |
| Average Volume | 2.33M |
| Market Cap | 91.97M |
| PE | -1.59 |
| EPS | -1.21 |
| Moving Average 50 Days | 1 |
| Moving Average 200 Days | 1.08 |
| Change | -0.06 |
If you invested $1000 in Shattuck Labs, Inc. (STTK) since IPO date, it would be worth $99.22 as of September 15, 2025 at a share price of $1.92. Whereas If you bought $1000 worth of Shattuck Labs, Inc. (STTK) shares 3 years ago, it would be worth $583.59 as of September 15, 2025 at a share price of $1.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
GlobeNewswire Inc.
Aug 26, 2025 10:30 AM GMT
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assumi
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
GlobeNewswire Inc.
Aug 21, 2025 2:17 PM GMT
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to dose the first participant in it
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
GlobeNewswire Inc.
Aug 05, 2025 10:30 AM GMT
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate proceeds antici